Chronic kidney disease. Chronic kidney disease
Conditions
Interventions
Intervention 1: Intervention group: The group receiving potassium citrate tablets will take them daily, with one to three doses, depending on the patients initial condition. The prescribed dose will b
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Minimum age of 18 years Chronic kidney disease stages 3, 4, and 5. Plasma bicarbonate level less than 20 mmol/L. Clinically stable condition. Consent to participate in the study.
Exclusion criteria
Exclusion criteria: Use of diuretics, potassium, or potassium supplements within the past 3 months. Chronic sepsis. Poorly controlled hypertension (>150/90 mmHg). Overt congestive heart failure (EF below 20%). Pregnancy and lactation. History of cystinuria. History of inflammatory bowel diseases. History of hyperparathyroidism. Use of warfarin. Use of vitamin or antioxidant supplements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in GFR (Glomerular Filtration Rate). Timepoint: Measurements are taken before the intervention begins, followed by reassessment of GFR and the patients' clinical status in the second week, first month, third month, and finally at the sixth month after the intervention. Method of measurement: GFR will be re-measured using the Modified MDRD formula. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse drug. Timepoint: Adverse events will be recorded after the intervention at the second week, first month, third month, and finally at the sixth month. Method of measurement: Adverse events will be recorded throughout the treatment period using a checklist approved by two specialists: a nephrologist and a pharmacologist.;Serum bicarbonate level. Timepoint: Measurements are taken before the intervention begins, followed by reassessment of serum bicarbonate levels in the second week, first month, third month, and finally at the sixth month after the intervention. Method of measurement: Potassium levels will be measured through blood sampling and laboratory testing.;Creatinine. Timepoint: Measurements are taken before the intervention begins, followed by reassessment of serum creatinine levels in the second week, first month, third month, and finally at the sixth month after the intervention. Method of measurement: Creatinine levels will be measured through blood sampling and laboratory testing.;Venous Blood Gas (VBG). Timepoint: Measurements are taken before the intervention begins, followed by reassessment of VBG levels in the second week, first month, third month, and finally at the sixth month after the intervention. Method of measurement: VBG levels will be measured through blood sampling and laboratory testing. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNavid Najarpour
Ahvaz University of Medical Sciences
Outcome results
None listed